A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

Sponsor

Amgen (Industry)

Overall Status

Completed

CT.gov ID

NCT05988021

Collaborator

(none)

Enrollment

Location

Arms

5.7

Actual Duration (Months)

2.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective of this clinical trial is to evaluate the effect of a high-fat, high-calorie meal on the pharmacokinetic (PK) profile of CCX168, following oral administration of a single dose of 30 mg CCX168 to healthy volunteers.

Condition or Disease	Intervention/Treatment	Phase
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis	Drug: CCX168	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

16 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Masking:

None (Open Label)

Primary Purpose:

Basic Science

Official Title:

An Open-Label, Phase 1 Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

Actual Study Start Date :

Dec 3, 2015

Actual Primary Completion Date :

Feb 9, 2016

Actual Study Completion Date :

May 25, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cohort 1: Sequence ABCD Participants assigned to sequence ABCD will receive the following treatments: Period 1: Single dose of 30 mg CCX168 after a high-fat, high-calorie meal (Treatment A). Period 2: After a washout period of ≥ 10 days, single dose of 30 mg CCX168 in the fasted state (Treatment B). Period 3: After a washout period of ≥ 10 days, single dose of 3 mg CCX168 in the fasted state (Treatment C). Period 4: 24 hours after the 3 mg CCX168 dose in Period 3, single dose of 100 mg CCX168 on Day 1, and then 100 mg CCX168 twice daily from Day 2 through Day 6. On Day 7, only a morning dose of 100 mg CCX168 (Treatment D).	Drug: CCX168 Administered orally.
Experimental: Cohort 2: Sequence BACD Participants assigned to sequence BACD will receive the following treatments: Period 1: Single dose of 30 mg CCX168 in the fasted state (Treatment B). Period 2: After a washout period of ≥ 10 days, single dose of 30 mg CCX168 after a high-fat, high-calorie meal (Treatment A). Period 3: After a washout period of ≥ 10 days, single dose of 3 mg CCX168 in the fasted state (Treatment C). Period 4: 24 hours after the 3 mg CCX168 dose in Period 3, single dose of 100 mg CCX168 on Day 1, and then 100 mg CCX168 twice daily from Day 2 through Day 6. On Day 7, only a morning dose of 100 mg CCX168 (Treatment D).	Drug: CCX168 Administered orally.

Arm

Intervention/Treatment

Experimental: Cohort 1: Sequence ABCD

Participants assigned to sequence ABCD will receive the following treatments: Period 1: Single dose of 30 mg CCX168 after a high-fat, high-calorie meal (Treatment A). Period 2: After a washout period of ≥ 10 days, single dose of 30 mg CCX168 in the fasted state (Treatment B). Period 3: After a washout period of ≥ 10 days, single dose of 3 mg CCX168 in the fasted state (Treatment C). Period 4: 24 hours after the 3 mg CCX168 dose in Period 3, single dose of 100 mg CCX168 on Day 1, and then 100 mg CCX168 twice daily from Day 2 through Day 6. On Day 7, only a morning dose of 100 mg CCX168 (Treatment D).

Drug: CCX168

Administered orally.

Experimental: Cohort 2: Sequence BACD

Participants assigned to sequence BACD will receive the following treatments: Period 1: Single dose of 30 mg CCX168 in the fasted state (Treatment B). Period 2: After a washout period of ≥ 10 days, single dose of 30 mg CCX168 after a high-fat, high-calorie meal (Treatment A). Period 3: After a washout period of ≥ 10 days, single dose of 3 mg CCX168 in the fasted state (Treatment C). Period 4: 24 hours after the 3 mg CCX168 dose in Period 3, single dose of 100 mg CCX168 on Day 1, and then 100 mg CCX168 twice daily from Day 2 through Day 6. On Day 7, only a morning dose of 100 mg CCX168 (Treatment D).

Drug: CCX168

Administered orally.

Outcome Measures

Primary Outcome Measures

Maximum Plasma Concentration (Cmax) of CCX168 [Up to 35 days]
Time of Cmax (Tmax) of CCX168 [Up to 35 days]
Area Under the Plasma Concentration-time Curve (AUC) of CCX168 From Time 0 to Time t (AUC0-t) [Up to 35 days]
AUC of CCX168 From Time 0 to Infinity (AUC0-inf) [Up to 35 days]

Secondary Outcome Measures

Number of Participants Experiencing Clinically Significant Changes in Electrocardiogram (ECG) Parameters [Up to 35 days]
Number of Participants Experiencing Adverse Events (AEs) [Up to 35 days]
Number of Participants Experiencing Clinically Significant Changes in Laboratory Parameters [Up to 35 days]
Number of Participants Experiencing Clinically Significant Changes in Vital Sign Parameters [Up to 35 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Male or female participants, aged 18-55 years inclusive, who are in generally good health, whose body mass index is 19.0 to 32.0 kg/m^2 inclusive;
Willing and able to give written Informed Consent and to comply with the requirements of the study protocol;
Negative result of the human immunodeficiency virus screen, the hepatitis B screen, and the hepatitis C screen;
Judged to be healthy by the Investigator, based on medical history, physical examination (including ECG, and clinical laboratory assessments. Participants with clinical laboratory values that are outside of normal limits and/or with other abnormal clinical findings that are judged by the Investigator not to be of clinical significance may be entered into the study;
Female participants of childbearing potential, or male participants with partners of childbearing potential may participate if adequate contraception is used during, and for at least 90 days after, any administration of study medication.

Exclusion Criteria:

Women who are pregnant, lactating, or have a positive serum pregnancy test at screening or check-in (Day -2);
Myocardial infarction or active ischemic heart disease within 12 months before screening;
Significant abnormal ECG: Pacemaker, any conduction abnormality associated with a QRS ≥120 msec, poorly-defined or abnormal T wave morphology precluding end of T measurement, abnormal rhythm for age, evidence of previous myocardial infarction (Q waves, S-T segment changes), sinus pauses > 2.5 seconds, ventricular couplets, triplets or other arrhythmia, symptomatic or asymptomatic;
Has any of the following abnormalities:

Heart rate <40 or >100 bpm
PR interval <110 or ≥220 msec
QRS duration ≥120 msec
QTcF interval <350 or >450 msec;

History of additional significant risk factors for torsade de pointes, including heart failure, hypokalemia, hypocalcemia, hypomagnesemia, family history of long QT syndrome;
Used a prescription and/or over-the-counter medication, with the exception of ibuprofen, hormonal contraceptives, and multi-vitamins, within 14 days prior to check-in;
History within the three months prior to check-in of use of tobacco and/or nicotine-containing products;
History within one year prior to check-in of illicit drug use;
History of alcohol abuse at any time in the past;
Has a history or presence of any form of cancer within the 5 years prior to check-in, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis;
For at least 14 days prior to check-in and throughout the blood sample collection period, participants will not be allowed to eat any food or drink any beverage containing alcohol, grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard greens) and charbroiled meats;
History or presence of unexplained syncope or family history of sudden death, or any medical condition or disease which, in the opinion of the Investigator, may place the participants at unacceptable risk for study participation;
Donated or lost more than 350 mL of blood or blood products within 56 days prior to screening, or donated plasma within 7 days of dosing;
Participant's hemoglobin less than 11.5 g/dL for women or less than 13.0 g/dL for men at screening or check-in, confirmed by a repeat measurement;
Participated in any clinical study of an investigational product within 30 days prior to dosing, or within 5 half-lives after dosing;
Participant has any evidence of hepatic disease; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, or bilirubin greater than 1.5 times the upper limit of normal at screening or check-in;
Participant's white blood cell count is below the lower limit of normal at screening or check-in, confirmed by a repeat measurement;
Participant has any evidence of renal impairment; serum creatinine greater than 1.5 times the upper limit of normal at screening or check-in;
Participant's urine tested positive at screening and/or on check-in for any of the following: opioids, amphetamines and methamphetamines, cannabinoids, benzodiazepines, barbiturates, cocaine, cotinine, ecstasy, methadone, phencyclidine, tri-cyclic antidepressants, or alcohol (Breathalyzer test allowed for alcohol).